Bio-Rad Reports Third-Quarter 2021 Financial Results

Rhea-AI Summary

Bio-Rad Laboratories reported third-quarter 2021 net sales of $747.0 million, a 15.4% increase from $647.3 million year-over-year. The gross margin improved to 58.6% from 56.7% in Q3 2020. The Life Science segment sales rose 15.3% to $373.5 million, while Clinical Diagnostics saw a 15.5% increase to $372.2 million. Net income surged to $3,928.0 million or $129.96 per diluted share, compared to $1,314.8 million or $43.64 in the prior year. The company updated its 2021 guidance, now expecting 12-13% currency-neutral revenue growth.

Positive

• Net sales increased by 15.4% to $747.0 million.
• Gross margin improved to 58.6% from 56.7%.
• Net income rose to $3,928.0 million ($129.96 per share).
• Life Science segment net sales increased by 15.3%.
• Clinical Diagnostics segment net sales increased by 15.5%.
• Updated guidance for 2021 expects 12-13% currency-neutral revenue growth.

Negative

• European market sales declined despite overall revenue growth.
• Sales growth in COVID-19-related products moderated.

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2021.

Third-quarter 2021 net sales were $747.0 million, an increase of 15.4 percent compared to $647.3 million reported for the third quarter of 2020. On a currency-neutral basis, quarterly sales increased 13.8 percent compared to the same period in 2020. Third-quarter gross margin was 58.6 percent compared to 56.7 percent during the third quarter in 2020.

Life Science segment net sales for the third quarter were $373.5 million, an increase of 15.3 percent compared to the same period in 2020. On a currency-neutral basis, Life Science segment sales increased by 13.9 percent compared to the same quarter in 2020. Currency-neutral sales growth was primarily attributed to sales of our Droplet Digital PCR^® and Process Media product lines, as well as back royalties from a legal settlement. On a geographic basis, Life Science currency-neutral year-over-year sales grew across the Americas and Asia but declined in Europe. Excluding COVID-19-related sales, European region revenue posted a double-digit percent increase from the year ago period.

Clinical Diagnostics segment net sales for the third quarter were $372.2 million, an increase of 15.5 percent compared to the same period in 2020. On a currency-neutral basis, net sales increased 13.7 percent versus the same quarter last year. Currency-neutral sales were up for all product lines and across all regions, primarily driven by higher utilization in lab operations as businesses recover from the COVID-19 pandemic.

Income from operations during the third quarter of 2021 was $156.8 million versus $109.6 million during the same quarter last year.

Net income for the third quarter of 2021 was $3,928.0 million, or $129.96 per share on a diluted basis, versus $1,314.8 million, or $43.64 per share on a diluted basis, during the same period in 2020. Net income for the third quarter of 2021 and 2020 was impacted by the recognition of changes in the fair market value of equity securities, primarily related to the holdings of our investment in Sartorius AG. The effective tax rate for the third quarter of 2021 was 21.8 percent, compared to 21.9 percent for the same period in 2020. The tax rates for both periods were driven by the large unrealized gain in equity securities.

“We are pleased with our performance in the third quarter, which reflected strength across many product lines,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer. “During the quarter, demand continued for products associated with COVID-19 testing and research, though at a more moderate level,” he said.

GAAP Results
	Q3 2021	Q3 2020
Revenue (millions)	$747.0	$647.3
Gross margin	58.6%	56.7%
Operating margin	21.0%	16.9%
Net income (millions)	$3,928.0	$1,314.8
Income per diluted share	$129.96	$43.64
Non-GAAP Results
	Q3 2021	Q3 2020
Revenue (millions)	$715.2	$647.3
Gross margin	57.9%	57.5%
Operating margin	19.4%	18.8%
Net income (millions)	$112.2	$90.3
Income per diluted share	$3.71	$3.00
A reconciliation between GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release. Non-GAAP adjustments include amortization of purchased intangibles; acquisition-related expenses and benefits; restructuring, impairment charges and valuation changes in equity-owned securities; gains and losses on equity-method investments; significant litigation charges or benefits and legal costs; and discrete income tax events and the income tax effect on these non-GAAP adjustments.

Non-GAAP net income and non-GAAP diluted income per share (non-GAAP EPS) are non-GAAP measures that exclude certain items detailed later in this press release under the heading “Non-GAAP Reporting.”

Non-GAAP net income for the third quarter of 2021 was $112.2 million, or $3.71 per share on a diluted basis, compared to $90.3 million, or $3.00 per share on a diluted basis, during the same period in 2020.

The non-GAAP effective tax rate for the third quarter of 2021 was 18.0 percent, compared to 22.5 percent for the same period in 2020. The lower rate in 2021 was driven by the geographic mix of earnings. In addition, the effective tax rate was lower as a result of an increase in compensation related tax deductions.

The following table represents a reconciliation of Bio-Rad’s reported net income and diluted income per share to non-GAAP net income and non-GAAP diluted income per share for the three and nine months ended September 30, 2021 and 2020:

	(in thousands, except per share data)	Three Months Ended September 30,						Nine Months Ended September 30,
			2021			2020			2021			2020
GAAP net income		$	3,928,033		$	1,314,824		$	5,819,561		$	2,967,165
	Legal settlements		(28,083	)		-			(28,619	)		-
	Amortization of purchased intangibles		7,097			7,163			21,032			20,257
	Legal matters		2,325			5,977			15,501			10,395
	Acquisition related costs (benefits)		-			165			(40	)		(837	)
	Restructuring costs (benefits)		15			(1,111	)		67,799			(827	)
	Valuation gain on equity-owned securities		(4,868,659	)		(1,580,350	)		(7,078,753	)		(3,591,509	)
	Loss on equity-method investments		1,899			183			5,579			2,634
	Other non-recurring items		-			-			-			(11,680	)
	Income tax effect on non-GAAP adjustments		1,069,577			343,401			1,554,100			800,631
Non-GAAP net income		$	112,204		$	90,252		$	376,160		$	196,229
GAAP diluted income per share		$	129.96		$	43.64		$	192.76		$	98.46
Non-GAAP diluted income per share		$	3.71		$	3.00		$	12.46		$	6.51

On a reported basis, net sales for the first three quarters of 2021 increased 24.7 percent to $2,189.8 million compared to $1,755.8 million for the same period in 2020. On a currency-neutral basis, net sales grew 21.2 percent.

Year-to-date net income for 2021 was $5,819.6 million, or $192.76 per share on a fully diluted basis, compared to $2,967.2 million, or $98.46 per share during the same period in 2020. The COVID-19 pandemic positively impacted overall results for the first three quarters of the year. On a non-GAAP basis net income for the first three quarters of 2021 was $376.2 million, or $12.46 per share, compared to $196.2 million, or $6.51 per share during the same period in 2020.

“Throughout the year we adapted well to challenges posed by the COVID-19 pandemic, supporting our customers and ensuring the safety of our employees while continuing to make progress on our core strategies,” Mr. Schwartz said. “As we head into the end of 2021, we will continue to build on the progress we’ve made during the first three quarters and expect to generate improved operating profit over 2020,” he added.

2021 Financial Outlook

For the full year 2021, the company has updated its guidance and now anticipates non-GAAP currency-neutral revenue growth between 12 to 13 percent and an estimated non-GAAP operating margin of approximately 19.5 percent. Management will discuss this outlook in greater detail on the third-quarter 2021 financial results conference call.

Use of Non-GAAP Reporting and Currency-Neutral

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including non-GAAP net income and non-GAAP EPS, which exclude amortization of acquisition-related intangible assets, certain acquisition-related expenses and benefits, restructuring charges, asset impairment charges, valuation changes of equity-owned securities, gains and losses on equity-method investments, and significant legal-related charges or benefits and associated legal costs. Non-GAAP net income and non-GAAP EPS also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, income tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies. More specifically, management adjusts for the excluded items for the following reasons:

Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the term of amortization can vary significantly and are unique to each acquisition or purchase. We believe that excluding amortization of purchased intangible assets allows the users of our financial statements to better review and understand the historic and current results of our operations, and also facilitates comparisons to peer companies.

Acquisition-related expenses and benefits: we incur expenses or benefits with respect to certain items associated with our acquisitions, such as transaction costs, professional fees for assistance with the transaction; valuation or integration costs; changes in the fair value of contingent consideration, gain or loss on settlement of pre-existing relationships with the acquired entity; or adjustments to purchase price. We exclude such expenses or benefits as they are related to acquisitions and have no direct correlation to the operation of our on-going business.

Restructuring, impairment charges and valuation changes in equity-owned securities and gains and losses on equity-method investments: we incur restructuring and impairment charges on individual or groups of employed assets and charges and benefits arising from valuation changes in equity-owned securities and gains and losses on equity-method investments, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business. Although these events are reflected in our GAAP financials, these unique transactions may limit the comparability of our on-going operations with prior and future periods.

Significant litigation charges or benefits and legal costs: we may incur charges or benefits as well as legal costs in connection with litigation and other contingencies unrelated to our core operations. We exclude these charges or benefits, when significant, as well as legal costs associated with significant legal matters, because we do not believe they are reflective of on-going business and operating results.

Income tax expense: we estimate the tax effect of the excluded items identified above to determine a non-GAAP annual effective income tax rate applied to the pretax amount in order to calculate the non-GAAP provision for income taxes. We also adjust for items for which the nature and/or tax jurisdiction requires the application of a specific tax rate or treatment.

From time to time in the future, there may be other items excluded if we believe that doing so is consistent with the goal of providing useful information to investors and management.

Percentage sales growth in currency-neutral amounts are calculated by translating prior period sales in each local currency using the current period’s monthly average foreign exchange rates for that currency and comparing that to current period sales.

There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results. The presentation of this additional information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP in the United States. Investors should review the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

Conference Call and Webcast

Management will discuss third-quarter ended September 30, 2021 results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) October 28, 2021. To listen, call 844-200-6205 within the U.S. or 929-526-1599 outside the U.S., access code: 535686. You may also listen to the conference call live via a webcast that is available on the “Investor Relations” section of our website under “Quarterly Results” at bio-rad.com. The webcast will be available for up to a year.

BIO-RAD and DROPLET DIGITAL PCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. Please visit bio-rad.com for further information.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding estimated future financial performance or results; anticipating non-GAAP currency-neutral revenue growth of between 12 to 13 percent and an estimated non-GAAP operating margin of approximately 19.5 percent for the full year 2021; continuing to build on the progress we’ve made during the first three quarters as we head into the end of 2021; and expecting to generate improved operating profit over 2020. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "anticipate," "estimate," "expect," "continue," "believe," "will," "project," "assume," "may," "intend," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration, severity and impact of the COVID-19 pandemic, global economic conditions, our ability to develop and market new or improved products, our ability to compete effectively, foreign currency exchange fluctuations, supply chain issues, reductions in government funding or capital spending of our customers, international legal and regulatory risks, product quality and liability issues, our ability to integrate acquired companies, products or technologies into our company successfully, changes in the healthcare industry, and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Income
(In thousands, except per share data)
(Unaudited)
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2021				2020				2021				2020
Net sales		$	747,049			$	647,263			$	2,189,776			$	1,755,787
Cost of goods sold			309,614				279,952				950,116				778,120
Gross profit			437,435				367,311				1,239,660				977,667
Selling, general and administrative expense			216,150				198,165				655,428				581,119
Research and development expense			64,481				59,546				201,784				160,833
Income from operations			156,804				109,600				382,448				235,715
Interest expense			426				5,728				1,187				17,158
Foreign currency exchange losses, net			2,232				776				542				2,478
Change in fair market value of equity securities			(4,868,659	)			(1,580,350	)			(7,078,753	)			(3,591,509	)
Other expense (income), net			579				(1,015	)			(16,732	)			(21,517	)
Income before income taxes			5,022,226				1,684,461				7,476,204				3,829,105
Provision for income taxes			(1,094,193	)			(369,637	)			(1,656,643	)			(861,940	)
Net income		$	3,928,033			$	1,314,824			$	5,819,561			$	2,967,165
Basic earnings per share:
Net income per basic share		$	131.75			$	44.24			$	195.29			$	99.75
Weighted average common shares - basic			29,814				29,721				29,800				29,746
Diluted earnings per share:
Net income per diluted share		$	129.96			$	43.64			$	192.76			$	98.46
Weighted average common shares - diluted			30,224				30,128				30,190				30,137

Bio-Rad Laboratories, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
	September 30,			December 31,
	2021			2020
	(Unaudited)
Current assets:
Cash and cash equivalents	$	859,902		$	662,205
Short-term investments		482,756			334,473
Accounts receivable, net		417,714			419,424
Inventories, net		588,911			622,253
Other current assets		117,003			101,480
Total current assets		2,466,286			2,139,835
Property, plant and equipment, net		476,648			491,371
Operating lease right-of-use assets		204,191			202,136
Goodwill, net		291,916			291,916
Purchased intangibles, net		177,073			199,497
Other investments		16,230,635			9,561,140
Other assets		106,631			86,723
Total assets	$	19,953,380		$	12,972,618
Current liabilities:
Accounts payable, accrued payroll and employee benefits	$	380,344		$	362,326
Current maturities of long-term debt		1,739			1,798
Income and other taxes payable		54,050			57,335
Other current liabilities		213,783			210,077
Total current liabilities		649,916			631,536
Long-term debt, net of current maturities		10,645			12,258
Other long-term liabilities		3,960,441			2,448,884
Total liabilities		4,621,002			3,092,678
Total stockholders' equity		15,332,378			9,879,940
Total liabilities and stockholders' equity	$	19,953,380		$	12,972,618

Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
	Nine Months Ended
	September 30,
	2021				2020
Cash flows from operating activities:
Cash received from customers	$	2,177,199			$	1,741,431
Cash paid to suppliers and employees		(1,597,938	)			(1,406,427	)
Interest paid, net		(1,848	)			(11,066	)
Income tax payments, net		(103,902	)			(51,539	)
Other operating activities		25,086				18,195
Net cash provided by operating activities		498,597				290,594
Cash flows from investing activities:
Payments for acquisitions		-				(96,655	)
Other investing activities		(229,954	)			86,514
Net cash used in investing activities		(229,954	)			(10,141	)
Cash flows from financing activities:
Payments on long-term borrowings		(1,645	)			(1,780	)
Other financing activities		(58,419	)			(99,377	)
Net cash used in financing activities		(60,064	)			(101,157	)
Effect of foreign exchange rate changes on cash		(11,174	)			3,154
Net increase in cash, cash equivalents, and restricted cash		197,405				182,450
Cash, cash equivalents, and restricted cash at beginning of period		667,115				662,651
Cash, cash equivalents, and restricted cash at end of period	$	864,520			$	845,101
Reconciliation of net income to net cash provided by operating activities:
Net income	$	5,819,561			$	2,967,165
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		100,075				101,938
Reduction in the carrying amount of right-of-use assets		29,311				27,694
Changes in working capital		(14,538	)			(44,360	)
Other		(5,435,812	)			(2,761,843	)
Net cash provided by operating activities	$	498,597			$	290,594

Bio-Rad Laboratories, Inc.
Reconciliation of GAAP financial measures to non-GAAP financial measures
(In thousands, except per share data)
(Unaudited)
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including non-GAAP net income and non-GAAP diluted income per share (non-GAAP EPS), which exclude amortization of acquisition-related intangible assets; certain acquisition-related expenses and benefits; restructuring charges; asset impairment charges; valuation changes of equity-owned securities; gains and losses on equity-method investments; and significant legal-related charges or benefits and associated legal costs. Non-GAAP net income and non-GAAP EPS also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies.
		Three Months Ended							Three Months Ended							Nine Months Ended							Nine Months Ended
		September 30,				% of			September 30,				% of			September 30,				% of			September 30,				% of
		2021				revenue			2020				revenue			2021				revenue			2020				revenue
GAAP net sales		$	747,049						$	647,263						$	2,189,776						$	1,755,787
Legal settlements			(31,843	)						-							(31,843	)						-
Non-GAAP net sales		$	715,206						$	647,263						$	2,157,933						$	1,755,787
GAAP cost of goods sold		$	309,614						$	279,952						$	950,116						$	778,120
Amortization of purchased intangibles			(4,678	)						(4,841	)						(13,903	)						(13,700	)
Legal settlements			(4,071	)						-							(3,535	)						-
Restructuring benefits (costs)			(52	)						237							(25,241	)						1,705
Non-GAAP cost of goods sold		$	300,813						$	275,348						$	907,437						$	766,125
GAAP gross profit		$	437,435			58.6	%		$	367,311			56.7	%		$	1,239,660			56.6	%		$	977,667			55.7	%
Amortization of purchased intangibles			4,678							4,841							13,903							13,700
Legal settlements			(27,772	)						-							(28,308	)						-
Restructuring (benefits) costs			52							(237	)						25,241							(1,705	)
Non-GAAP gross profit		$	414,393			57.9	%		$	371,915			57.5	%		$	1,250,496			57.9	%		$	989,662			56.4	%
GAAP selling, general and administrative expense		$	216,150						$	198,165						$	655,428						$	581,119
Amortization of purchased intangibles			(2,419	)						(2,322	)						(7,129	)						(6,557	)
Legal matters			(2,325	)						(5,977	)						(15,501	)						(10,395	)
Acquisition related benefits (costs) (1)			-							(165	)						40							837
Restructuring benefits (costs)			299							815							(27,507	)						(1,992	)
Non-GAAP selling, general and administrative expense		$	211,705						$	190,516						$	605,331						$	563,012
GAAP research and development expense		$	64,481						$	59,546						$	201,784						$	160,833
Restructuring benefits (costs)			(262	)						59							(15,051	)						1,114
Non-GAAP research and development expense		$	64,219						$	59,605						$	186,733						$	161,947
GAAP income from operations		$	156,804			21.0	%		$	109,600			16.9	%		$	382,448			17.5	%		$	235,715			13.4	%
Legal settlements			(27,772	)						-							(28,308	)						-
Amortization of purchased intangibles			7,097							7,163							21,032							20,257
Legal matters			2,325							5,977							15,501							10,395
Acquisition related (benefits) costs (1)			-							165							(40	)						(837	)
Restructuring (benefits) costs			15							(1,111	)						67,799							(827	)
Non-GAAP income from operations		$	138,469			19.4	%		$	121,794			18.8	%		$	458,432			21.2	%		$	264,703			15.1	%
GAAP change in fair market value of equity securities		$	(4,868,659	)					$	(1,580,350	)					$	(7,078,753	)					$	(3,591,509	)
Valuation (loss) gain on equity-owned securities			4,868,659							1,580,350							7,078,753							3,591,509
Non-GAAP change in fair market value of equity securities		$	-						$	-						$	-						$	-
GAAP other (income) expense, net		$	579						$	(1,015	)					$	(16,732	)					$	(21,517	)
(Loss) gain on equity-method investments			(1,899	)						(183	)						(5,579	)						(2,634	)
Legal settlements			311							-							311							-
Other non-recurring items (3)			-							-							-							11,680
Non-GAAP other (income) expense, net		$	(1,009	)					$	(1,198	)					$	(22,000	)					$	(12,471	)
GAAP income before income taxes		$	5,022,226						$	1,684,461						$	7,476,204						$	3,829,105
Legal settlements			(28,083	)						-							(28,619	)						-
Amortization of purchased intangibles			7,097							7,163							21,032							20,257
Legal matters			2,325							5,977							15,501							10,395
Acquisition related (benefits) costs (1)			-							165							(40	)						(837	)
Restructuring (benefits) costs			15							(1,111	)						67,799							(827	)
Valuation loss (gain) on equity-owned securities			(4,868,659	)						(1,580,350	)						(7,078,753	)						(3,591,509	)
Loss (gain) on equity-method investments			1,899							183							5,579							2,634
Other non-recurring items (3)			-							-							-							(11,680	)
Non-GAAP income before income taxes		$	136,820						$	116,488						$	478,703						$	257,538
GAAP provision for income taxes		$	(1,094,193	)					$	(369,637	)					$	(1,656,643	)					$	(861,940	)
Income tax effect of non-GAAP adjustments (2)			1,069,577							343,401							1,554,100							800,631
Non-GAAP provision for income taxes		$	(24,616	)					$	(26,236	)					$	(102,543	)					$	(61,309	)
GAAP net income		$	3,928,033			525.8	%		$	1,314,824			203.1	%		$	5,819,561			265.8	%		$	2,967,165			169.0	%
Legal settlements			(28,083	)						-							(28,619	)						-
Amortization of purchased intangibles			7,097							7,163							21,032							20,257
Legal matters			2,325							5,977							15,501							10,395
Acquisition related (benefits) costs (1)			-							165							(40	)						(837	)
Restructuring (benefits) costs			15							(1,111	)						67,799							(827	)
Valuation loss (gain) on equity-owned securities			(4,868,659	)						(1,580,350	)						(7,078,753	)						(3,591,509	)
Loss (gain) on equity-method investments			1,899							183							5,579							2,634
Other non-recurring items (3)			-							-							-							(11,680	)
Income tax effect of non-GAAP adjustments (2)			1,069,577							343,401							1,554,100							800,631
Non-GAAP net income		$	112,204			15.7	%		$	90,252			13.9	%		$	376,160			17.4	%		$	196,229			11.2	%
GAAP diluted income per share		$	129.96						$	43.64						$	192.76						$	98.46
Legal settlements			(0.93	)						-							(0.95	)						-
Amortization of purchased intangibles			0.23							0.24							0.70							0.67
Legal matters			0.08							0.20							0.51							0.34
Acquisition related (benefits) costs (1)			-							0.01							-							(0.03	)
Restructuring (benefits) costs			-							(0.04	)						2.25							(0.03	)
Valuation loss (gain) on equity-owned securities			(161.09	)						(52.45	)						(234.47	)						(119.17	)
Loss (gain) on equity-method investments			0.06							0.01							0.18							0.09
Other non-recurring items (3)			-							-							-							(0.39	)
Income tax effect of non-GAAP adjustments (2)			35.40							11.39							51.48							26.57
Non-GAAP diluted income per share		$	3.71						$	3.00						$	12.46						$	6.51
GAAP diluted weighted average shares used in per share calculation			30,224							30,128							30,190							30,137
Shares included in non-GAAP net income per share, but excluded from GAAP net loss per share as they would have been anti-dilutive			-							-							-							-
Non-GAAP diluted weighted average shares used in per share calculation			30,224							30,128							30,190							30,137
(1) Release of contingent consideration and other acquisition-related (benefits) expenses.
(2) Excluded items identified in the reconciliation schedule are tax effected by application of a non-GAAP effective tax rate. The non-GAAP tax provision is adjusted for items, the nature of which and/or tax jurisdiction requires the application of a specific tax rate or treatment.
(3) Gain on the sale of a division (2020).
2021 Financial Outlook
Forecasted non-GAAP operating margin excludes 96 basis points related to amortization of purchased intangibles. Forecasted non-GAAP operating margin does not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance, such as foreign currency fluctuations, future gains or losses associated with certain legal matters, acquisitions and restructuring activities.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211028006011/en/

Investor Contact:

Edward Chung, Vice President, Investor Relations

510-741-6577

ir@bio-rad.com

Media Contact:

Tina Cuccia, Manager, Corporate Communications

510-741-6063

tina_cuccia@bio-rad.com

Source: Bio-Rad Laboratories, Inc.

FAQ

What were Bio-Rad's Q3 2021 financial results?

Bio-Rad reported Q3 2021 net sales of $747.0 million, a 15.4% increase from the previous year, with a net income of $3,928.0 million.

What is Bio-Rad's guidance for 2021?

Bio-Rad expects a non-GAAP currency-neutral revenue growth of 12-13% for the full year 2021.

What were the sales figures for Bio-Rad's Life Science segment in Q3 2021?

The Life Science segment net sales were $373.5 million, reflecting a 15.3% year-over-year increase.

What are the main factors contributing to Bio-Rad's revenue growth?

Revenue growth was largely driven by the Droplet Digital PCR® and Process Media product lines, along with back royalties from a legal settlement.

How did Bio-Rad's performance compare between different regions?

Sales grew in the Americas and Asia, while Europe experienced a decline, although European revenue (excluding COVID-19 sales) showed double-digit growth.